Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-cash Items (2023 - 2025)

Kura Oncology (KURA) has disclosed Non-cash Items for 3 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 2165.15% to $12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.5 million, a 2165.15% increase, with the full-year FY2025 number at $12.5 million, up 2165.15% from a year prior.
  • Non-cash Items was $12.5 million for Q4 2025 at Kura Oncology, down from $41.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $49.6 million in Q1 2023 to a low of $551000.0 in Q4 2024.
  • A 3-year average of $36.7 million and a median of $44.6 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: plummeted 95.72% in 2024, then surged 2165.15% in 2025.
  • Kura Oncology's Non-cash Items stood at $12.9 million in 2023, then tumbled by 95.72% to $551000.0 in 2024, then soared by 2165.15% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Non-cash Items are $12.5 million (Q4 2025), $41.0 million (Q3 2025), and $43.7 million (Q2 2025).